Skip to Content

ASCO GI 2024: Targeting HER2 in Gastroesophageal Adenocarcinoma

HER2-targeted therapy, particularly known for breast cancer treatment, has in recent years gained traction in the treatment of gastroesophageal adenocarcinoma as well. In this article, based on a piece published by ASCO Daily News, we will provide a brief introduction to the developments in this field.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top